Phage Display Library Screening for SARS-CoV-2 Antibody Development

The novel coronavirus, named SARS-CoV-2, is now rapidly spreading across the world after originating in the city of Wuhan, China. Human-to-human transmission of this virus has been identified in familial case cluster reports, and additional cases continue to be confirmed in different cities and countries around the world.

To develop therapeutic strategies, neutralizing antibody (NAb) is emerged and establishes the best evidence that protective immunity has been provided and biological tests of neutralization reveal a correlation with protection. Creative Biolabs has long-term devoted to the development and application of phage display technology. With years of experience, our scientists have developed several phage display based platforms and tailored hundreds of particular libraries. We are pleased to use our extensive experience and advanced platform to offer custom services of phage display library screening for the development of neutralizing antibody to SARS-CoV-2.

Phage Display Technique

Fig.1 Application of biopanning with phage-displayed random peptide libraries. (Wu, 2016)

Phage display is an in vitro selection technique, widely used in the laboratory, by which a peptide or protein is fused with a bacteriophage coat protein and exhibited on the surface of a virion. Phage display random libraries enable functional access to the proteins and provide a physical linkage between genotype (encoding DNA) and phenotype (displayed protein). These libraries are then built up by assembling millions of genetically modified bacteriophages, which can be performed for further screening and selection. Compared with the traditional hybridoma technology, phage display library screening has enormous advantages in identifying novel antibodies for diagnostic, therapeutic, or prophylactic applications. The expression of functional antibody fragments on the surface of phage has revolutionized the process of antibody discovery and engineering.

A neutralizing antibody targeting the protein on the surface of SARS-CoV-2 may be the first therapy contemplated in the academic area. For the rapid spreading SARS-CoV-2, conventional tools of screening mice for neutralizing antibodies are too slow. As such, phage display libraries can be quickly used to sperate lead candidates for viral neutralization.

Fig.2 Types of antibody library design. (Ch’ng, 2016)

Phage Display Library Screening for SARS-CoV-2 Antibody Development at Creative Biolabs

With broad expertise in the field of infectious diseases, Creative Biolabs acts promptly with an intensive need to find options to help defense the illness and preclude potential death. We are proud to introduce our phage display platform and would like to develop new and effective neutralizing antibody therapies in this outbreak.

At Creative Biolabs, the concept of screening can be applied very broadly. It can be loosely implemented to identify antibodies with high titers or identify optimal conditions for antibody production. In the discovery of antibody drugs, screening refers to a lot of preparation and is typically the bottleneck in the whole process. High-quality reagents and standard assays are critical for a successful screening outcome. We offer optimized reagents, ideal screening and validation steps for SARS-CoV-2 antibody development as below.

• Reagents, including materials used for screening, antibody production, and for mechanistic research 
  

  cDNA Expression plasmids

  Cell lines Purified proteins

  Reference antibodies Target orthologs

• Screening and validation steps
  

  Primary assays PK/PD

  Secondary assays In vivo efficacy studies

  Tertiary assays Toxicity studies

Creative Biolabs is one of the well-recognized experts who are professional in applying advanced phage display technologies for a broad range of project objectives. With leading technology platforms in phage antibody library constuction & screening, Creative Biolabs provides a full range of innovative integrated services to assist global clients or medical institute to enable the development of multiple neutralizing antibodies for SARS-CoV-2. Through our high-throughput system, clients could accelerate their research with the most comprehensive view of antibody and with reducing project costs and timelines. For more information or details, please directly contact us or consult our technical supports online.

References

1. Wu, C.H.; et al. Advancement and applications of peptide phage display technology in biomedical science. J. Biomed. Sci. 2016, 23(8): 1-14.
2. Ch’ng, A.C.W.; et al. Phage display-derived antibodies: application of recombinant antibodies for diagnostics. INTECH. 2016, 7: 107-135.

For Research Use Only. We do not provide direct services or products for patients.